Wall Street brokerages predict that Chimerix, Inc. (NASDAQ:CMRX) will announce sales of $810,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Chimerix’s earnings, with estimates ranging from $500,000.00 to $1.00 million. Chimerix posted sales of $650,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 24.6%. The business is scheduled to report its next quarterly earnings results on Monday, November 6th.

On average, analysts expect that Chimerix will report full-year sales of $810,000.00 for the current financial year, with estimates ranging from $1.75 million to $4.43 million. For the next fiscal year, analysts expect that the company will report sales of $3.75 million per share, with estimates ranging from $1.00 million to $6.25 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Chimerix.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.05. The business had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $1.28 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%.

Several equities research analysts recently issued reports on the company. ValuEngine cut Chimerix from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Wednesday, August 9th.

TRADEMARK VIOLATION WARNING: “$810,000.00 in Sales Expected for Chimerix, Inc. (CMRX) This Quarter” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/20/810000-00-in-sales-expected-for-chimerix-inc-cmrx-this-quarter.html.

Shares of Chimerix (CMRX) opened at 5.03 on Friday. The stock’s market cap is $236.64 million. The firm has a 50-day moving average price of $5.11 and a 200-day moving average price of $5.11. Chimerix has a 12 month low of $3.66 and a 12 month high of $6.64.

Several institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Chimerix by 8.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 39,628 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 3,042 shares during the last quarter. State Street Corp boosted its holdings in shares of Chimerix by 7.3% during the 2nd quarter. State Street Corp now owns 828,936 shares of the biopharmaceutical company’s stock worth $4,515,000 after purchasing an additional 56,600 shares during the last quarter. Numeric Investors LLC boosted its holdings in shares of Chimerix by 4.2% during the 2nd quarter. Numeric Investors LLC now owns 1,271,253 shares of the biopharmaceutical company’s stock worth $6,928,000 after purchasing an additional 51,322 shares during the last quarter. Voya Investment Management LLC boosted its holdings in shares of Chimerix by 18.3% during the 2nd quarter. Voya Investment Management LLC now owns 29,203 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 4,526 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Chimerix by 38.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,448,250 shares of the biopharmaceutical company’s stock worth $7,893,000 after purchasing an additional 404,914 shares during the last quarter. Institutional investors and hedge funds own 67.53% of the company’s stock.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.